Melodia Therapeutics is advancing a next-generation DPP1 inhibitor to transform the treatment of severe neutrophil-driven inflammatory diseases.
Our Novel Approach
Achieves precise enzyme inhibition without requiring covalent attachment through a highly reactive nitrile group that is commonly used in other DPP1 inhibitors
Our Unique Mechanism
By selectively inhibiting DPP1 in this unique way, we aim to deliver a best-in-class therapy with improved efficacy and safety compared to earlier agents.
Our Expertise in Development
Backed by leading science and a team with proven expertise in drug development, Melodia is building a pipeline to address major unmet needs.
Our Vision and Mission
We focus on respiratory, dermatologic, and systemic inflammatory disorders where current treatments are inadequate, and aim to become a leader in anti-granulocyte therapies.
